Actualités MyMD Pharmaceuticals Inc - MYMD | Actions NASDAQ

Votre Hub pour des idées et discussions en direct en temps réel

MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking...

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A...

Current Report Filing (8-k)

0001321834 false 0001321834 2023-03-02 2023-03-02 iso4217:USD xbrli:shares...

MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical

-- DEA scientific review concludes Supera-CBD will not be classified as a regulated chemical or require scheduling during development -- MyMD...

Current Report Filing (8-k)

0001321834 false 0001321834 2023-02-28 2023-02-28 iso4217:USD xbrli:shares...

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

-- Study results comparing the anti-inflammatory effects of MYMD-1® to Enbrel (etanercept) accepted for poster presentation -- MyMD...

Current Report Filing (8-k)

0001321834 false 0001321834 2023-02-21 2023-02-21 iso4217:USD xbrli:shares...

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Filed Pursuant to Rule 424(b)(5) Registration No. 333-254698 Prospectus Supplement (To prospectus dated May 11...

Current Report Filing (8-k)

0001321834 false 0001321834 2023-02-21 2023-02-21 iso4217:USD xbrli:shares...

MyMD Announces $15 Million Offering with Existing Investors

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking...

Amended Statement of Ownership (sc 13g/a)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Current Report Filing (8-k)

0001321834 false 0001321834 2023-02-01 2023-02-01 iso4217:USD xbrli:shares...

Current Report Filing (8-k)

0001321834 false 0001321834 2022-12-14 2022-12-14 iso4217:USD xbrli:shares...

Current Report Filing (8-k)

0001321834 false 0001321834 2022-12-06 2022-12-06 iso4217:USD xbrli:shares...

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

- Preclinical and early clinical studies of MYMD-1®, an oral, small-molecule, selective TNF-α inhibitor, suggest future potential to disrupt the...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Abonnez-vous à un compte ADVFN en remplissant le formulaire ci-dessous!

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

MyMD Pharmaceuticals Inc (MYMD)

Votre Hub pour des idées et discussions en direct en temps réel

MYMD Actualités

MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Current Report Filing (8-k)

MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical

Current Report Filing (8-k)

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

Current Report Filing (8-k)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Current Report Filing (8-k)

MyMD Announces $15 Million Offering with Existing Investors

Amended Statement of Ownership (sc 13g/a)

Current Report Filing (8-k)

Current Report Filing (8-k)

Current Report Filing (8-k)

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

MyMD Pharmaceuticals Inc (MYMD) Actualités

MyMD Pharmaceuticals Inc (MYMD)

Votre Hub pour des idées et discussions en direct en temps réel

MYMD Actualités

MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Current Report Filing (8-k)

MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical

Current Report Filing (8-k)

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

Current Report Filing (8-k)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Current Report Filing (8-k)

MyMD Announces $15 Million Offering with Existing Investors

Amended Statement of Ownership (sc 13g/a)

Current Report Filing (8-k)

Current Report Filing (8-k)

Current Report Filing (8-k)

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Abonnez-vous à un compte ADVFN en remplissant le formulaire ci-dessous!

Supprimer les publicités